University of Missouri School of Medicine
Columbia, Missouri, 65212, United States
Location status: Recruiting
NCT Number: NCT05235464
Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas "lean" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.
Interested in participating?
Request Info45 year–75 year
All sexes
Interventional
Not applicable
Columbia, Missouri, 65212, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard meal
Meal with high animal protein content
Meal with high plant protein content
Meal with high plant protein content and additional leucine
Time frame: baseline before meal intake to 3 hours after the meal
Change in proatherogenic pathway activation
Time frame: baseline before meal intake to 3 hours after the meal
Change in plasma amino acid concentrations
Time frame: baseline before meal intake to 3 hours after the meal
Change in plasma glucose concentration
Time frame: baseline before meal intake to 3 hours after the meal
Change in plasma concentrations of glucoregulatory hormones
Time frame: baseline (before meal intake) and postprandially (after the meal)
Endothelial function assessed as reactive hyperemia index
Contact information is provided by the study sponsor or research team.
University of Missouri-Columbia
Other
Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis
Acronym: HPA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07613294
Arterial Occlusive Diseases, Arteriosclerosis
La Jolla, California, United States
View Trial DetailsNCT01399385
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial DetailsNCT07719894
Arterial Occlusive Diseases, Arteriosclerosis
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsNCT00353782
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial Details